Jaye L. Viner - Concepedia

Author

Jaye L. Viner

National Cancer Institute

Also Known As

J L Viner, J VINER, J Viner, J. L. Viner, J. Viner, J.L. Viner, JAYE L. VINER, Jaye L Viner, Jaye L. Viner, Jaye Viner

104

Publications

5.6K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute The University of Texas MD Anderson Cancer Center National Institutes of Health Memorial Sloan Kettering Cancer Center Georgetown University

About

Jaye L. Viner is an author at National Cancer Institute specializing in medicine, oncology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.8K
2	Engineering	2	2	63
3	Arts	1	1	26
4	Education	1	1	33
5	Management	1	1	33

Jaye L. Viner

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research Martin A. Cheever, James P. Allison, Andrea Stern Ferris, Clinical Cancer Research Cancer AntigensImmunologyImmunoeditingPathologyCancer Registration	2009	1.4K
Celecoxib for the Prevention of Sporadic Colorectal Adenomas Monica M. Bertagnolli, Craig Eagle, Ann G. Zauber, New England Journal of Medicine	2006	1K
Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials Scott D. Solomon, Janet Wittes, Peter Finn, Circulation	2008	354
Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial Craig A. Elmets, Jaye L. Viner, Alice P. Pentland, JNCI Journal of the National Cancer Institute	2010	240
Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity Partha S. Chowdhury, Jaye L. Viner, Richard Beers, Proceedings of the National Academy of Sciences	1998	221
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial Anas Younes, Jesús G. Berdeja, Manish R. Patel, The Lancet Oncology Hematological MalignancyMedicineImmune Checkpoint InhibitorMultiple MyelomaPharmacotherapy	2016	180
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers Kaiming Sun, Ruzanna Atoyan, Mylissa Borek, Molecular Cancer Therapeutics	2016	138
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of α-Difluoromethylornithine in Subjects with Previous History of Skin Cancer Howard H. Bailey, KyungMann Kim, Ajit Kumar Verma, Cancer Prevention Research	2010	109
Anti-Tumor Activity of K1-LysPE38QQR, an Immunotoxin Targeting Mesothelin, a Cell-Surface Antigen Overexpressed in Ovarian Cancer and Malignant Mesothelioma Raffit Hassan, Jaye L. Viner, Qingcheng Wang, Journal of Immunotherapy	2000	70
Altered Expression of Insulin Receptor Isoforms in Breast Cancer Jiaqi Huang, Chris Morehouse, Katie Streicher, PLoS ONE	2011	61

Page 1